PREVENOX: ALTERNATIVE FOR THE NON-HORMONAL TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

Abstract

During the climacteric stage and postmenopause important physical and psychological changes occur that occur with clinical manifestations and diseases, where we can find Osteoporosis; silent disease that has been called ¨The silent epidemic of the 21st century¨. In recent years, evaluations of studies on menopausal hormonal therapy and the effects of hormonal and non-hormonal replacement therapy in the prevention and treatment of Osteoporosis have increased. Prevenox is a mixture of very high molecular weight aliphatic primary acids obtained from cane wax, with lipid-lowering, antioxidant, anti-platelet aggregation effects, demonstrated in preclinical and clinical studies. It has also shown beneficial pleiotropic effects on vascular and extravascular targets (and within the latter, its osteoprotective effects stand out), as well as being safe and very well tolerated. The objective of this review is to address Prevenox as an alternative for the non-hormonal treatment of postmenopausal women with osteoporosis. It is concluded that Prevenox constitutes an alternative for the non-hormonal treatment of postmenopausal women with osteoporosis. Future clinical, randomized, long-term, comparative studies with a larger sample size should confirm this hypothesis.